Mylan Keeps Options Open As Perrigo Pursuit Continues
This article was originally published in The Pink Sheet Daily
After Teva dropped its offer for Mylan, the generic drug maker says it is exploring all options as it continues to pursue Perrigo. In the meantime, it has increased its ability to acquire its target through a tender offer.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.